Abstract
Purpose
The aim of this study was to investigate the impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 polymorphisms on vincristine neurotoxicity. We subsequently assessed the impact of ABCB1 polymorphisms on intracellular vincristine accumulation.
Methods
Children treated for solid tumors were enrolled in the study (n = 26) and received 1.5 mg/m² of vincristine per course. Individual pharmacokinetic parameters and CYP3A4, CYP3A5, and ABCB1 genotypes were available from a previous analysis. A global toxicity score (pain, peripheral neurotoxicity, and gastrointestinal toxicity) was collected at each course. Vincristine in plasma and PBMCs were quantified by LC-MS/MS.
Results
Vincristine plasma and intracellular concentrations ranged from 0.40 to 89.6 ng/ml and from 0.00225 to 1.85 ng/106 cells over a 24-h interval, respectively. The global toxicity score ranged from 0 to 6 and was not correlated with individual pharmacokinetics parameters. Neurotoxicity events (global score ≥3) were observed in 8 patients but the incidence was not influenced by the different studied polymorphisms. The global toxicity score was correlated with age, body surface area, and dose in mg. A trend to higher intracellular/plasma ratio of vincristine was found for patients with heterozygous diplotype (CGC-TTT) of ABCB1.
Conclusions
None of the different genetic covariates nor plasma and intracellular exposure was predictive of the observed neurotoxicity in our pediatric population. Nevertheless, the heterozygote diplotype of ABCB1 appears to influence the intracellular accumulation of vincristine. Owing to the small sample size, further evaluations are needed in a larger patient cohort.
This is a preview of subscription content, log in via an institution to check access.
References
Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421–427
McGuire SA, Gospe SM Jr, Dahl G (1989) Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. Med Pediatr Oncol 17:520–523
Desai ZR, Van den Berg HW, Bridges JM et al (1982) Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8:211–214
Donelli MG, Zucchetti M, Munzone E et al (1998) Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 34:33–46
Kamaluddin M, McNally P, Breatnach F et al (2001) Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 90:1204–1207
Crom WR, de Graaf SS, Synold T et al (1994) Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 125:642–649
Dennison JB, Kulanthaivel P, Barbuch RJ et al (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317–1327
Renbarger JL, McCammack KC, Rouse CE et al (2008) Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 50:769–771
Egbelakin A, Ferguson MJ, Macgill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361–367
Guilhaumou R, Simon N, Quaranta S et al (2010) Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumor diseases. Cancer Chemother Pharmacol. [Epub ahead of print]
Lengsfeld AM, Dietrich J, Schultze-Maurer B (1982) Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study. Cancer Res 42:3798–3805
Kobayashi H, Takemura Y, Holland JF et al (1998) Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect. Biochem Pharmacol 15(55):1229–1234
Groninger E, Koopmans P, Kamps W et al (2003) An automated HPLC method to determine intracellular vincristine concentrations in mononuclear cells of children with acute lymphoblastic leukemia. Ther Drug Monit 25:441–446
Rahmani R, Zhou XJ (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17:269–281
Guilhaumou R, Solas C, Rome A et al (2010) Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples. J Chromatogr B Analyt Technol Biomed Life Sci 878:423–427
Zipursky A, Bow E, Seshadri RS et al (1976) Leukocyte density and volume in normal subjects and in patients with acute lymphoblastic leukemia. Blood 48:361–371
Dennison JB, Jones DR, Renbarger JL et al (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553–563
Pasquier E, André N, Braguer D (2007) Targeting microtubules to inhibit angiogenesis and disrupt tumor vasculature: implications for cancer treatment. Curr Cancer Drug Targ 7:566–581
Wang F, Zhou F, Kruh GD et al (2010) Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol 12:1043–1049
Langholz B, Skolnik JM, Barrett JS et al (2010) Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the children’s oncology group. Pediatr Blood Cancer. [Epub ahead of print]
Acknowledgments
This work was supported by a grant from Assistance Publique-Hôpitaux de Marseille.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guilhaumou, R., Solas, C., Bourgarel-Rey, V. et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68, 1633–1638 (2011). https://doi.org/10.1007/s00280-011-1745-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-011-1745-2